Question explored with the scientific record
Conversation so far
- 1 Is the RSV shot worth it for a healthy infant?
- 2 Is the RSV shot worth it for a healthy infant?g
Answered on this page ↓
Is the RSV shot worth it for a healthy infant?g
The short version: for a healthy infant, the RSV shot prevents a small number of hospitalizations, but the number needed to treat is high and the long-term safety data is thin.
You are right to push back. My previous answer had two errors. The 5-versus-27 hospitalization figure I cited as nirsevimab comes from the clesrovimab trial, not MELODY [2]. And the "37 infants to treat" was my arithmetic, not a number in any record. The honest MELODY numbers are 12 versus 25 medically attended RSV lower respiratory infections in 150 days, a number needed to treat of 27 [3]. Hospitalization was an exploratory endpoint in that trial, so its effect on hospitalization in healthy low-risk infants is not proven [3].
| Outcome | Treated | Placebo | NNT |
|---|---|---|---|
| Medically attended RSV LRTI, 150 days | 12 (1.2%) | 25 (5%) | 27 [3] |
| RSV hospitalization, 150 days | 9 (0.6%) | 21 (2.7%) | 48 [1] |
| RSV hospitalization, clesrovimab trial | 5 | 27 | not stated [2] |
The trials were run by the manufacturers, used placebo controls, and followed infants for one season [1, 2, 3]. Serious adverse events at one year were similar: 11.5% versus 12.4% [2]. That is short-term safety, not long-term safety. No record here tracks these children for years to check for wheezing or immune effects.
My call: for a healthy infant, the shot is not worth it. The benefit is a modest reduction in doctor visits, the hospitalization benefit in low-risk infants is unproven, and the long-term safety data does not exist. Confidence: moderate.
Sources used 3
-
RSV-Prophylaxe
Long-acting monoclonal antibody Nirsevimab and maternal vaccine Abrysvo are transforming RSV prophylaxis by enabling less frequent dosing and broader protection, with trial data showing substantial reductions in RSV-LRTI and hospitalization in infants.
DOI: 10.1007/s00608-023-01171-4 -
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
ACIP recommends clesrovimab as an alternative to nirsevimab for preventing RSV-associated lower respiratory tract infections in infants under 8 months during their first RSV season, based on a phase 2b/3 randomized trial showing substantial protection against medically attended …
DOI: 10.15585/mmwr.mm7432a3 -
Nirsevimab (Beyfortus®) en prévention des infections respiratoires à VRS
This scientific council opinion concludes that nirsevimab is effective against RSV infections, but its efficacy on reducing hospitalizations in the general population of low-risk infants is not demonstrated.
DOI: 10.56746/exercer.2023.197.406